For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human IL-11 Detection Kit is designed for detection and quantitation of human interleukin-11 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Human interleukin 11 (IL11) is a non-glycosylated protein of 23 kDa (179 amino acids). It is produced by bone marrow stromal cells (fibroblasts) and also by a variety of mesenchymal cells. IL11 stimulates megakaryocytopoiesis, activates osteoclasts, inhibits epithelial cell proliferation and apoptosis, and inhibits macrophage mediator production. IL-11 also possesses anti-inflammatory activity, and has been proposed as a therapeutic agent in the treatment of chronic inflammatory diseases, such as Crohn's disease and rheumatoid arthritis. IL11 activity is mediated by the IL-11 receptor (IL-11R) that has been reported in a wide variety of cells and tissues. IL11 binds to the IL-11R protein alone with low affinity; the affinity increases when IL-11R is associated with is signal transducer: gp130.
|Assay Target Class||Cytokine|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...